Comparative study of labetalol and nifedipine in management of non- severe preeclampsia and its fetomaternal outcome


  • Delphine T. Rose Department of Obstetrics and Gynecology, Thanjavur Medical College, Tamil Nadu, India
  • Jeyarani P. Department of Obstetrics and Gynecology, Thanjavur Medical College, Tamil Nadu, India



Hypertension, Labetalol, Non-severe preeclampsia, Nifedipine


Background: In developed countries, 16 percent of maternal deaths were attributed to hypertensive disorders. Of hypertensive disorders, the preeclampsia syndrome, either alone or superimposed on chronic hypertension, is the most dangerous. The incidence of preeclampsia in nulliparous populations ranged from 3 to 10 percent.

Methods: The present study was conducted at Government Raja Mirasudhar Hospital, Thanjavur Medical College, Thanjavur, Tamil Nadu, India from October 2017 to October 2018. The study consisted of 100 antenatal women with non-severe preeclampsia. The efficacy of labetalol verses nifedipine in its management was studied along with the fetomaternal outcome.

Results: In this study, in the labetalol and in the nifedipine groups adequate control of blood pressure was achieved. However, labetalol was well tolerated by our women without much side effects.

Conclusions: The present study indicates both labetalol and nifedipine are equally efficacious in the control of hypertension in non-severe preeclampsia. Pathology of the disease was not altered significantly in both the groups. There was no significant difference in the neonatal outcome between the two groups.


Hypertensive Disorders In: Williams Obstetrics, 25th ed, New York, NY: McGraw-Hill. 2018:40:711.

Odigboegwu O, Pan LJ, Chatterjee P. Use of antihypertensive drugs during preeclampsia. Front Cardiovasc Med. 2018;5:50.

Lakshmi KV, Lakshmi K. Labetalol Vs Nifedipine in treatment of pregnancy induced hypertension. Int J Sci Res. 2016:5(12):10-1.

Ganesh SK, Unnikrishnan B, Nagaraj K, Jayaram S. Determinants of pre-eclampsia: A case-control study in a district hospital in South India. IJCM. 2010;35(4):502-5.

Yadav S, Saxena U, Yadav R, Gupta S. Hypertensive disorders of pregnancy and maternal and foetal outcome: a case controlled study. J Indian Med Assoc. 1997;95(10):548-51.

Sibai BM, Cunningham FG. Prevention of preeclampsia. In Lindheimer MD, Roberts JM, Cunningham FG editors: Chesley’s hypertensive Disorders of Pregnancy. 3rd edition, Elsevier, NewYork. 2009;215.

Von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355:87-92.

Bharathi KN, Prasad KVSRG, Jagannath Pairu, Naik BC. Comparison of anti hypertensive efficacy of labetol, nefedipine and methyl dopa in pregnancy induced hypertension. Pharmacol Online. 2009;3:670-8.

Patel NK, Gadhavi M, Gorasia D, Pandya MR. Comparative evaluation of antihypertensive drugs in the management of pregnancy-induced hypertension. Int J Basic Clin Pharmacol. 2012;1(3):174-7.

Waterman EJ, Magee LA, Lim KI, Skoll A, Rurak D, von Dadelszen P. Do commonly used oral anti-hypertensives alter fetal or neonatal heart rate characteristics? A systematic review. Hypert Pregn. 2009:155-69.






Original Research Articles